ATE260121T1 - Membraneinbau von texaphyrinen - Google Patents

Membraneinbau von texaphyrinen

Info

Publication number
ATE260121T1
ATE260121T1 AT97927923T AT97927923T ATE260121T1 AT E260121 T1 ATE260121 T1 AT E260121T1 AT 97927923 T AT97927923 T AT 97927923T AT 97927923 T AT97927923 T AT 97927923T AT E260121 T1 ATE260121 T1 AT E260121T1
Authority
AT
Austria
Prior art keywords
texaphyrin
molecule conjugate
lipophilic molecule
loaded
cells loaded
Prior art date
Application number
AT97927923T
Other languages
English (en)
Inventor
Stuart W Young
Meredith Wright
Jonathan L Sessler
Tarak D Mody
Darren Magda
Original Assignee
Pharmacyclics Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc, Univ Texas filed Critical Pharmacyclics Inc
Application granted granted Critical
Publication of ATE260121T1 publication Critical patent/ATE260121T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—3D [Three Dimensional] image rendering
    • G06T15/10—Geometric effects
    • G06T15/20—Perspective computation
    • G06T15/205—Image-based rendering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Computer Graphics (AREA)
  • Computing Systems (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Geometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
AT97927923T 1996-06-04 1997-06-04 Membraneinbau von texaphyrinen ATE260121T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65794796A 1996-06-04 1996-06-04
PCT/US1997/009501 WO1997046262A2 (en) 1996-06-04 1997-06-04 Membrane incorporation of texaphyrins

Publications (1)

Publication Number Publication Date
ATE260121T1 true ATE260121T1 (de) 2004-03-15

Family

ID=24639282

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97927923T ATE260121T1 (de) 1996-06-04 1997-06-04 Membraneinbau von texaphyrinen

Country Status (12)

Country Link
EP (1) EP0954336B1 (de)
JP (1) JP2000512279A (de)
CN (1) CN1225591A (de)
AT (1) ATE260121T1 (de)
AU (1) AU727138B2 (de)
BR (1) BR9710685A (de)
CA (1) CA2257225A1 (de)
DE (1) DE69727833T2 (de)
IL (1) IL127315A (de)
NO (1) NO985645L (de)
NZ (1) NZ333072A (de)
WO (1) WO1997046262A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
US6375930B2 (en) 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
BR9714642A (pt) * 1996-12-11 2000-10-03 Pharmacyclics Inc "uso de texafirina na preparação de um medicamento para uso em diagnóstico e terapia ocular"
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6183727B1 (en) * 1998-05-19 2001-02-06 Arizona Board Of Regents Use of long-wavelength electromagnetic radiation and photoprotective tumor localizing agents for diagnosis
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
EP1206288B1 (de) * 1999-08-02 2007-01-10 The Regents Of The University Of Michigan Zielgerichtete fiberlose radiative effektoren
US6944493B2 (en) 1999-09-10 2005-09-13 Akora, Inc. Indocyanine green (ICG) compositions and related methods of use
AU7106400A (en) * 1999-09-10 2001-04-10 Akorn, Inc. Fluorescent dye angiography and dye-enhanced photocoagulation
US6351663B1 (en) 1999-09-10 2002-02-26 Akorn, Inc. Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US6319273B1 (en) * 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
US7112671B2 (en) 2000-08-30 2006-09-26 Pharmacyclics, Inc. Non-symmetric tripyrranes in the synthesis of novel macrocycles
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7449454B2 (en) 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
EP1684723A4 (de) * 2003-11-21 2007-06-20 Fujifilm Corp Kontrastmittel mit liposomen mit hydrophober chelierverbindung
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
WO2016165006A1 (en) * 2015-04-17 2016-10-20 University Health Network Texaphyrin-phospholipid conjugates and methods of preparing same
CN111265674A (zh) * 2020-03-24 2020-06-12 浙江大学医学院附属第四医院(浙江省义乌医院、浙江大学医学院附属第四医院医共体) 一种造影剂、造影剂的制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5120411A (en) * 1989-12-21 1992-06-09 Board Of Regents, The University Of Texas System Photodynamic activity of sapphyrins
US5591422A (en) * 1995-06-02 1997-01-07 Pharmacyclics, Inc. Texaphyrin complexes having improved functionalization

Also Published As

Publication number Publication date
WO1997046262A3 (en) 1998-03-12
IL127315A (en) 2003-05-29
IL127315A0 (en) 1999-09-22
AU3226497A (en) 1998-01-05
JP2000512279A (ja) 2000-09-19
CN1225591A (zh) 1999-08-11
DE69727833T2 (de) 2005-01-13
NZ333072A (en) 2000-06-23
AU727138B2 (en) 2000-12-07
BR9710685A (pt) 2000-01-11
EP0954336B1 (de) 2004-02-25
CA2257225A1 (en) 1997-12-11
NO985645D0 (no) 1998-12-03
EP0954336A2 (de) 1999-11-10
NO985645L (no) 1999-02-03
DE69727833D1 (de) 2004-04-01
WO1997046262A2 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
ATE260121T1 (de) Membraneinbau von texaphyrinen
CA1324051C (en) Ultrasound enhancement of transdermal drug delivery
Black et al. Composite tissue (limb) allografts in rats
DE3650572D1 (de) Kontrastmittel zur darstellung des leber-gallensystems mittels nmr-kontrastmittel
ATE99544T1 (de) Liposomale radiologische kontrastmittel.
JPH05501856A (ja) 脳及び筋肉組織傷害による浮腫の治療剤
Green et al. Human central nervous system and plasma pharmacology of mitoxantrone
Stewart et al. The treatment of patients with interstitial cystitis, with special reference to intravesical DMSO
Ley et al. Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: neurobehavior, histopathology, and pharmacokinetics
Hjelm et al. BIOCHEMICAL EFFECTS OF AROMATIC AMINES: II. CYANOSIS, METHAEMOGLOBINAEMIA AND HEINZ‐BODY FORMATION INDUCED BY A LOCAL ANAESTHETIC AGENT (PRILOCAINE)
Duray et al. Demonstration of cutaneous doxorubicin extravasation by rhodamine‐filtered fluorescence microscopy
BOWE Primary excision in third degree burns
RU2192817C2 (ru) Способ лечения частичной атрофии зрительного нерва
WO2007122280A1 (es) Uso del factor de crecimiento de hígado (lgf) como regenerador tisular pleiotrópico
RU2161036C2 (ru) Способ лечения хронических диффузных заболеваний печени
Piller et al. The effect of coumarin (5, 6 benzo-α-pyrone) on elicited members of the mononuclear system in dogs with chronic secondary lymphedema
RU2144364C1 (ru) Способ лечения больных с лимфедемой конечностей
Nuernberg et al. Anti-inflammatory effects and disposition of S-and R-flurbiprofen in the rat
McGuire et al. In vivo diffusion of lidocaine through tissue expanders
Moreau et al. Haemodynamic effects of octreotide in portal hypertensive rats receiving propranolol
Abdollahi et al. New approach to the efficacy of oximes in the management of acute organophosphates poisoning
Ushiyama et al. Physiological Effects of Continuous Whole-Body Exposure to Extremely Low Frequency Electromagnetic Fields With or Without Transient Magnetic Fields on Cerebral Microcirculation in Mice With Brain Tumors
Zima et al. The localisation of TPPS~ 4 in some organs and its possible nephrotoxicity in rats
UA29799A (uk) Спосіб профілактики та лікування післяопераційного панкреатиту
Romanova et al. Prevention of stress-induced cardio-and cerebrovascular disturbances by low-power laser irradiation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties